Patents Assigned to Shimoda Biotech (Pty) Ltd.
-
Patent number: 11452729Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: GrantFiled: July 17, 2020Date of Patent: September 27, 2022Assignee: SHIMODA BIOTECH (PTY) LTDInventor: Henk Swart
-
Publication number: 20210315905Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: ApplicationFiled: July 17, 2020Publication date: October 14, 2021Applicant: Shimoda Biotech (PTY) LtdInventor: Henk SWART
-
Publication number: 20200345751Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: ApplicationFiled: July 17, 2020Publication date: November 5, 2020Applicant: Shimoda Biotech (PTY) LtdInventor: Henk SWART
-
Patent number: 10758547Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: GrantFiled: June 6, 2017Date of Patent: September 1, 2020Assignee: Shimoda Biotech (PTY) LtdInventor: Henk Swart
-
Patent number: 9724355Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus crythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: GrantFiled: September 16, 2011Date of Patent: August 8, 2017Assignee: SHIMODA BIOTECH (PTY) LTDInventor: Henk Swart
-
Publication number: 20130274236Abstract: Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus crythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.Type: ApplicationFiled: September 16, 2011Publication date: October 17, 2013Applicant: SHIMODA BIOTECH (PTY) LTDInventor: Henk Swart
-
Patent number: 7803381Abstract: The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or G, and even more particularly, X is E or Q. Thus, a preferred amino acid sequence for the peptide is GPRLGYSWHE. The peptide may optionally include one or more additional D-amino acids at its N- or C-terminus, for example a cysteine residue or a series of linker amino acids, such as a plurality of glycine amino acid residues. Thus, a second preferred amino acid sequence for the peptide is GPRLGYSWHEC, which includes a cysteine residue at the C-terminus for conjugation purposes.Type: GrantFiled: November 7, 2003Date of Patent: September 28, 2010Assignee: Shimoda Biotech (Pty) Ltd.Inventor: Robert Peter Millar
-
Publication number: 20100184722Abstract: Provided are inclusion complexes comprising a sildenafil salt (e.g., sildenafil citrate) and alpha-cyclodextrin. The complexes may be useful treating various conditions, such as male erectile dysfunction and pulmonary hypertension. In some instances the inclusion complexes increase the solubility of sildenafil. Also provided are methods of producing the inclusion complexes, as well as methods of treatment, kits and unit dosages.Type: ApplicationFiled: December 18, 2009Publication date: July 22, 2010Applicant: Shimoda Biotech (Pty) LtdInventors: Henk Swart, Steyn Knoetze
-
Publication number: 20050238674Abstract: This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular and intravenous administration. The solutions contain diclofenac or diclofenac salt, cyclodextrin, and an antioxidant selected from monothioglycerol, or a combination of ethylene diamine tetra-acetic acid and N-acetyl-cysteine.Type: ApplicationFiled: November 30, 2004Publication date: October 27, 2005Applicant: Shimoda Biotech (Pty) Ltd.Inventors: Lawrence Penkler, Barry Daisley